- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04607252
Metformin Plus Megestrol Acetate as a Fertility-sparing Treatment in Patients With Atypical Endometrial Hyperplasia
March 24, 2022 updated by: Xiaojun Chen, Fudan University
Comparing Metformin Plus Megestrol Acetate With Megestrol Acetate Alone as a Fertility-sparing Treatment in Patients With Atypical Endometrial Hyperplasia
To verify whether metformin could improve the effect of progestin as fertility-sparing treatment in patients with atypical endometrial hyperplasia(AEH).
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
Whether metformin could improve the effect of progestin as fertility-sparing treatment in patients with atypical endometrial hyperplasia(AEH) is still not clear.
Our previous finding from subgroup analysis in a phase II randomized controlled trial showed that 39.6% of AEH patients in metformin plus megestrol acetate group achieved complete response, compared with 20.4% in group of megestrol acetate alone.
This trial aim to fully testify the effect of metformin in fertility-sparing treatment for AEH patients with adequate sample size.
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200011
- Obstetrics and Gynecology Hospital, Fudan University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- 18-45 years old;
- pathologically diagnosed with AEH for the first time;
- desire to preserve their fertility;
- no signs of suspicious myometrial invasion or extrauterine metastasis by enhanced magnetic resonance imaging (MRI), enhanced computed tomography (CT) or transvaginal ultrasonography (TVUS);
- no contraindication for metformin, megestrol acetate or pregnancy;
- no hormone or metformin treatment within 6 months before entering the trial;
- not pregnant when participating in the trial;
- willing to follow the trial arrangement after being fully informed of all the risks and inconveniences caused by the trial.
Exclusion Criteria:
Patients who had one or more of the following conditions:
- allergy history or contraindications for megestrol acetate or metformin;
- pregnant when initiating the study;
- alcoholism, severe infection, severe chronical diseases (dysfunction of heart, liver, lung or kidney);
- high risk of thrombosis;
- recurrent AEH;
- endometrial cancer;
- other malignancy history.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Metformin plus megestrol acetate
Metformin 1500mg per day plus megestrol acetate 160mg per day.
|
metformin 1500mg, per day, oral; megestrol acetate 160mg per day, oral
|
Active Comparator: Megestrol acetate
Megestrol acetate 160mg per day.
|
megestrol acetate 160mg per day, oral
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete response within 16 weeks of treatment
Time Frame: 16 weeks
|
reversion of AEH The reversion of AEH to proliferative or secretory endometrium
|
16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete response within 32 weeks of treatment
Time Frame: 32 weeks
|
The reversion of AEH to proliferative or secretory endometrium
|
32 weeks
|
Adverse events
Time Frame: 32 weeks
|
Adverse events during the treatment of metformin plus megestrol acetate or megestrol acetate alone
|
32 weeks
|
2-year recurrence rate
Time Frame: 2 years
|
recurrence rate within 2 years after the treatment
|
2 years
|
2-year pregnancy rate
Time Frame: 2 years
|
Pregnancy rate within 2 years after the treatment
|
2 years
|
2-year live-birth rate
Time Frame: 2 years
|
Live-birth rate within 2 years after the treatment
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: XIAOJUN CHEN, PhD, Obstetrics & Gynecology Hospital of Fudan University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 11, 2021
Primary Completion (Actual)
June 3, 2021
Study Completion (Actual)
June 3, 2021
Study Registration Dates
First Submitted
October 23, 2020
First Submitted That Met QC Criteria
October 28, 2020
First Posted (Actual)
October 29, 2020
Study Record Updates
Last Update Posted (Actual)
April 5, 2022
Last Update Submitted That Met QC Criteria
March 24, 2022
Last Verified
March 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Uterine Diseases
- Hyperplasia
- Endometrial Hyperplasia
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Antineoplastic Agents
- Antineoplastic Agents, Hormonal
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptives, Oral
- Contraceptive Agents, Female
- Contraceptives, Oral, Synthetic
- Contraceptives, Oral, Hormonal
- Central Nervous System Stimulants
- Appetite Stimulants
- Metformin
- Megestrol
- Megestrol Acetate
Other Study ID Numbers
- V01 2020-10
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
IPD Plan Description
Data will be shared with other researchers without patients' personal information after all the findings being published.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atypical Endometrial Hyperplasia
-
IRCCS Burlo GarofoloCompletedAtypical Endometrial Hyperplasia | Atypical Endometrial PolypsItaly
-
Zagazig UniversityCompletedAtypical Endometrial HyperplasiaEgypt
-
Fudan UniversityZhejiang Cancer Hospital; Shanghai 6th People's Hospital; Shanghai Changning...CompletedAtypical Endometrial HyperplasiaChina
-
West China Second University HospitalRecruitingAtypical Endometrial Hyperplasia | Endometrial CancerChina
-
Xiaojun ChenHuashan HospitalWithdrawnAtypical Endometrial Hyperplasia | Fertility Issues | Obese
-
Peking University People's HospitalPeking University; Beihang UniversityRecruitingAtypical Endometrial Hyperplasia | Endometrial Carcinoma Stage IChina
-
Krankenhaus Barmherzige Schwestern LinzCompletedEndometrial Cancer | Atypical HyperplasiaAustria
-
NYU Langone HealthCompletedAtypical Endometrial Hyperplasia | Endometrial CarcinomaUnited States
-
Peking University People's HospitalRecruitingAtypical Endometrial Hyperplasia | Endometrial Carcinoma Stage IChina
-
Fudan UniversityCompletedAtypical Endometrial HyperplasiaChina
Clinical Trials on Metformin plus Megestrol acetate
-
Xiaojun ChenZhejiang Cancer Hospital; Fudan University; Shanghai 6th People's Hospital; Shanghai...CompletedEndometrial Adenocarcinoma | Endometrial Atypical HyperplasiaChina
-
Southwest Oncology GroupNational Cancer Institute (NCI)CompletedBreast Cancer | Hot Flashes
-
Par Pharmaceutical, Inc.PRA Health SciencesTerminatedAnorexia | Weight Loss | CachexiaUnited States
-
Bristol-Myers SquibbCompletedHIV Infections | Anorexia | CachexiaUnited States
-
Endo PharmaceuticalsQuintiles, Inc.CompletedHIV Infections | Anorexia | Cachexia | HIV Wasting Syndrome | AIDS Wasting SyndromeUnited States, India, South Africa
-
Bristol-Myers SquibbCompletedHIV Infections | Anorexia | CachexiaUnited States
-
St. Vincent Medical Center - Los AngelesUnknownBreast Cancer | Malignant Mesothelioma | Endometrial CancerUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)CompletedFatigue | Unspecified Adult Solid Tumor, Protocol Specific | CachexiaUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedAnorexia | Lung Cancer | CachexiaUnited States
-
Bristol-Myers SquibbCompletedHIV Infections | Anorexia | CachexiaUnited States